FDA Warns GSK Over Manufacturing Violations In UK

Law360, New York (October 18, 2011, 3:57 PM EDT) -- The U.S. Food and Drug Administration on Tuesday published a warning letter sent to a GlaxoSmithKline PLC unit for allegedly not doing enough to prevent microbial contamination of drugs manufactured at a U.K. plant.

During a routine inspection in March, FDA officials uncovered significant violations of manufacturing regulations at SmithKline Beecham Ltd.'s plant in Worthing, West Sussex, according to the letter.

"These violations cause your drug products to be adulterated," the FDA's Oct. 7 letter said.

The only product the Worthing plant exports to the U.S....
To view the full article, register now.